Join
Live feed
·
PRReleasevia Quantisnow
BioXcel Therapeutics Inc. logo

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
BTAI· BioXcel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTAI (BioXcel Therapeutics Inc.) and more on Quantisnow.